Construction of the Chinese-Western Synergistic System for the Prevention and Treatment of Diabetic Lower Extremity Arterial Disease

GAO Hong, XIE Hongyan, LIANG Qingzhi, XIE Chunguang

Abstract

Diabetic lower extremity arterial disease (DLEAD) is characterized by a low rate of diagnosis, low awareness, low treatment rate, high disability rate, and high mortality. Due to a lack of comprehensive prevention and treatment strategies or an integrated technological system, DLEAD has become a bottleneck in the prevention and control of diabetes mellitus at present. Traditional Chinese medicine (TCM) treatment of DLEAD offers the advantages of syndrome differentiation, evidence-based treatment, and holistic regulation. However, it lacks a comprehensive understanding of the through-course pathogenesis and unified standardized syndrome criteria. TCM treatment of DLEAD exerts multi-target and multi-pathway network effects, but the advantageous links are still not fully understood. TCM treatments can delay the onset and development of DLEAD, but the efficacy evaluation system remains incomplete. Furthermore, there is a lack of high-quality evidence-based medical evidence and clinical consensus and guidelines. Therefore, based on the idea of zhi wei bing, or treating the disease before it develops, in Chinese medicine, and focusing on the prevention and control of DLEAD, we have constructed a synergistic technical system that integrates traditional Chinese and Western medicine for the prevention and control of DLEAD. This system integrates prevention, diagnosis, treatment, mechanisms, and applications, so as to enhance the clinical effects of DLEAD prevention and control, and to create a new paradigm for collaborative traditional Chinese medicine and western medicine in the field of chronic disease management.

 

Keywords: Diabetic lower extremity arterial disease, Integration of traditional Chinese medicine and western medicine, Preventive treatment of disease

 

Full Text:

PDF


References


CHANG Y T, TZENG I S, JANG S J, et al. TRENDPAD Study Group. Association between corrected QT interval and long-term cardiovascular outcomes in elderly patients who had undergone endovascular therapy for lower extremity arterial disease. Front Cardiovasc Med, 2023, 12(10): 1103520. doi: 10.3389/fcvm.2023.1103520.

YAN H, WANG Y H, ZHANG C H. Value of toe brachial index and anklebrachial index in diagnosis of diabeticlower extremity atherosclerotic disease. Chinese Journal of Diabetes, 2016, 24(8): 708-711. doi: 10.3969/j-issn.1006-6187.2016.08.010.

ZHANG X, RAN X, XU Z, et al. Epidemiological characteristics of lower extremity arterial disease in Chinese diabetes patients at high risk: a prospective, multicenter, cross-sectional study. J Diabetes Complications, 2018, 32(2): 150-156. doi: 10.1016/j.jdiacomp.2017.10.003.

Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition). Chinese Journal of Endocrinology and Metabolism, 2021, 37(4): 311-398. doi: 10.3760/cma.j. cn311282-20210304-00142.

Van den HAM H A, SOUVEREIN P C, KLUNGEL O H, et al. Major bleeding in users of direct oral anticoagulants in atrial fibrillation: a pooled analysis of results from multiple population-based cohort studies. Pharmacoepidemiol Drug Saf, 2021, 30(10): 1339-1352. doi: 10.1002/pds.5317.

RAY W, CHUNG C, MURRAY K, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA, 2018, 320(21): 2221-2230. doi: 10.1001/jama.2018.17242.

LÓPEZ-LÓPEZ J A, STERNE J A C, THOM H H Z, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ, 2017, 359(28): j5058. doi: 10.1136/bmj.j5058.

RAJPUT R, SINHA B, MAJUMDAR S, et al. Consensus statement on insulin therapy in chronic kidney disease. Diabetes Res Clin Pract, 2017, 127: 10-20. doi: 10.1016/j.diabres.2017.02.032.

. Chinese Endocrinologist Association, Chinese Medical Doctor Association. Chinese experts consensus for oral glucoselowering drugs therapy in type 2 diabetes mellitus patients with chronic kidney disease (2019 Update). Chinese Journal of Endocrinology and Metabolism, 2019, 35(6): 447-454. doi: 10.3760/cma.j.issn.1000-6699.2019.06.001.

Joint Committee on the Chinese Guidelines for Lipid Management. Chinese Guidelines for Lipid Management (2023). Chin Circul J, 2023, 38(3): 237-271. doi: 10.3969/j.issn.1000-3614.2023.03.001.

DI Y R, FENG Y N, YANG D H, et al. Network Meta-analysis of effects of different statins on liver function. Chin Gen Prac, 2021, 24(18): 2331-2341. doi: 10.12114/j.issn.1007-9572.2021.00.488.

LI Z, WEI D, WAN M X, et al. Research progress on drug-induced liverinjury induced by statins. Drug Eval Res, 2024, 47(5): 941-950. doi: 10.7501/j.issn.1674-6376.2024.05.004.

DOYLE-DELGADO K, CHAMBERLAIN J, SHUBROOK J, et al. Pharmacologic approaches to glycemic treatment of type 2 diabetes: synopsis of the 2020 american diabetes association’s standards of medical care in diabetes clinical guideline. Ann Intern Med, 2020, 173(10): 813-821. doi: 10.7326/M20-2470.

DUJIC T, ZHOU K, DONNELLY L A, et al. Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: a godarts study. Diabetes, 2015, 64(5): 1786-1793. doi: 10.2337/db14-1388.

MCCREIGHT J, BAILEY C, PEARSON E R. Metformin and the gastrointestinal tract. Diabetologia, 2016, 59(3): 426-435. doi: 10.1007/s00125-015-3844-9.

BLONDE L, DAILEY G E, JABBOUR S A, et al. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin, 2004, 20(4): 565-572. doi: 10.1185/ 030079904125003278.

WU F, LI G Q, ZHANG X C. Predictive value of neutrophil-to-lymphocyte ratio in patients with lower extremity arteriosclerosis obliterans after intrastent restenosis. Journal of Clinical Medicine in Practice, 2021, 25(7): 89-92. doi: 10.7619/jcmp.20201548.

KLEIN L, NATHAN S, MAEHARA A, et al. SCAI expert consensus statement on management of in-stent restenosis and stent thrombosis. J Soc Cardiovasc Angiogr Interv, 2023, 2(4): 100971. doi: 10.1016/j.jscai. 2023.100971.

KINSTNER C, LAMMER J, WILLFORT-EHRINGER A, et al. Paclitaxel-eluting balloon versus standard balloon angioplasty in in-stent restenosis of the superficial femoral and proximal popliteal artery: 1-year results of the pacuba trial. JACC Cardiovasc Interv, 2016, 9(13): 1386-1392. doi: 10. 1016/j.jcin.2016.04.012.

JIN L, TIAN Z B. Current status and challenges overinterventional treatment of lower limbarterial diseases. Chinese Journal of Interventional lmaging and Therapy, 2023, 20(5): 257-259. doi: 10.13929/j.issn.1672-8475.2023.05.001.

KATSANOS K, SPILIOPOULOS S, KITROU P, et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc, 2018, 7(24): e011245. doi: 10.1161/JAHA.118.011245.


Refbacks

  • There are currently no refbacks.